Real World Asparaginase Therapy Toxicity

Launched by ST. JUDE CHILDREN'S RESEARCH HOSPITAL · May 28, 2025

Keywords

ClinConnect Summary

This clinical trial is focused on understanding the side effects of asparaginase drugs, which are often used to treat acute lymphoblastic leukemia (ALL) and acute lymphoblastic lymphoma (LLy). The researchers want to learn more about both the short-term and long-term effects these medications might have on patients. This study is not yet recruiting participants, but it aims to help improve the care and safety of patients receiving these treatments.

To be eligible for the trial, participants must have a diagnosis of acute lymphoblastic leukemia, lymphoblastic lymphoma, or a specific type of mixed leukemia. They should also be enrolled in a particular treatment protocol and start receiving post-treatment therapy within ten days. It's important to note that individuals or their guardians must be willing to provide written consent to participate. If you or a loved one meets these criteria, this trial could provide valuable insights into the effects of asparaginase therapy.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Diagnosis of acute lymphoblastic leukemia, lymphoblastic lymphoma, or mixed phenotype acute leukemia
• • Enrolled on INITIALL and no more than 10 days after initiation of post-INITIALL therapy
• * Post-INITIALL therapy is:
• • Standard of Care (SOC)/Non Protocol Treatment Plan (NPTP) as per Total therapy or
• • SJALL23T and not scheduled to receive venetoclax
• Exclusion Criteria:
• • Inability or unwillingness of research participant or legal guardian/representative to give written informed consent.